{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:50:29Z","timestamp":1771462229135,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Combination regimens have shown superiority over single agents in the adjuvant treatment of resected pancreatic cancer (PC), but there are no data supporting definition of the best regimen. This work aimed to compare the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab\/paclitaxel in PC patients. A meta-analysis was performed for direct comparison between trials comparing combination regimens and gemcitabine monotherapy. Subsequently, an indirect comparison was made between trials investigating the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab\/paclitaxel because of the same control arm (gemcitabine). A total of three studies met the selection criteria and were included in our indirect comparison. Indirect comparisons for efficacy outcomes showed a benefit in terms of DFS (disease-free survival)\/EFS (event-free survival)\/RFS (relapse-free survival) for both mFOLFIRINOX versus gemcitabine+capecitabine (HR 0.69, 95% CI 0.52\u20130.91) and versus gemcitabine+nab\/paclitaxel (HR 0.67, 95% CI 0.50\u20130.90). No significant advantage was registered for OS (overall survival). Indirect comparisons for safety showed an increase in terms of G3-5 AEs (with the exception of neutropenia) for mFOLFIRINOX versus gemcitabine+capecitabine (RR 1.24, 95% CI 1.03\u20131.50), while no significant differences were observed versus gemcitabine+nab\/paclitaxel. According to our results, mFOLFIRINOX is feasible and manageable and could represent a first option for fit PC resected patients.<\/jats:p>","DOI":"10.3390\/cancers12030534","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T03:21:16Z","timestamp":1582773676000},"page":"534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4365-5683","authenticated-orcid":false,"given":"Antonio","family":"Galvano","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6299-7235","authenticated-orcid":false,"given":"Marta","family":"Castiglia","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari, Viale Orazio Flacco, 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7014-6828","authenticated-orcid":false,"given":"Oronzo","family":"Brunetti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d of Bari, Viale Orazio Flacco, 65, 70124 Bari, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vaccaro","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Gristina","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Barraco","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7169-3463","authenticated-orcid":false,"given":"Marco","family":"Bono","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Guercio","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppa","family":"Graceffa","sequence":"additional","affiliation":[{"name":"Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Fulfaro","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[{"name":"Oncology Department, IRCCS Sacro Cuore Don Calabria Hospital, 37024 Negrar, Verona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana","family":"Bazan","sequence":"additional","affiliation":[{"name":"Department of Experimental Biomedicine and Clinical Neurosciences, School of Medicine, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1056\/NEJMra1404198","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Ryan","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/nrdp.2016.22","article-title":"Pancreatic cancer","volume":"2","author":"Kleeff","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1245\/s10434-010-1200-3","article-title":"Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas","volume":"17","author":"Redmond","year":"2010","journal-title":"Ann. Surg. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: Current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","article-title":"Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma","volume":"267","author":"Groot","year":"2018","journal-title":"Ann. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(01)06651-X","article-title":"Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial","volume":"358","author":"Neoptolemos","year":"2001","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.297.3.267","article-title":"Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial","volume":"297","author":"Oettle","year":"2007","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/jama.2010.1275","article-title":"Adjuvant chemotherapy with fluorouracil plus folinic acid vs. gemcitabine following pancreatic cancer resection: A randomized controlled trial","volume":"304","author":"Neoptolemos","year":"2010","journal-title":"JAMA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","article-title":"Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01)","volume":"388","author":"Uesaka","year":"2016","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(16)32409-6","article-title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial","volume":"389","author":"Neoptolemos","year":"2017","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2019.37.15_suppl.4000","article-title":"APACT: Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P\/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma","volume":"37","author":"Tempero","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10637-018-0598-5","article-title":"Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: Retrospective analysis","volume":"36","author":"Kang","year":"2018","journal-title":"Invest. New Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ejso.2008.12.006","article-title":"Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma","volume":"35","author":"Sergeant","year":"2009","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4","article-title":"An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging","volume":"72","author":"Kayahara","year":"1993","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jamcollsurg.2011.09.022","article-title":"Management of patients with pancreatic adenocarcinoma: National trends in patient selection, operative management, and use of adjuvant therapy","volume":"214","author":"Mayo","year":"2012","journal-title":"J. Am. Coll. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jamcollsurg.2006.12.011","article-title":"Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy?","volume":"204","author":"Aloia","year":"2007","journal-title":"J. Am. Coll. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1245\/s10434-014-3722-6","article-title":"The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma","volume":"21","author":"Wu","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1756283X17713879","article-title":"Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions","volume":"10","author":"Lambert","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.3748\/wjg.v25.i23.2839","article-title":"Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges","volume":"25","author":"Yang","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Hubner","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1056\/NEJMe1813684","article-title":"A Glimmer of Hope for Pancreatic Cancer","volume":"379","author":"Kindler","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Schlick, K., Magnes, T., Ratzinger, L., Jaud, B., Weiss, L., Melchardt, T., Greil, R., and Egle, A. (2018). Novel models for prediction of benefit and toxicity with FOLFIRINOX treatment of pancreatic cancer using clinically available parameters. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0206688"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.21037\/jgo.2018.04.02","article-title":"Retrospective comparison of the efficacy and the toxicity of standard and modified FOLFIRINOX regimens in patients with metastatic pancreatic adenocarcinoma","volume":"9","author":"Camandaroba","year":"2018","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"749\u2013e224","DOI":"10.1634\/theoncologist.2018-0900","article-title":"Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1\/Oxaliplatin\/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma","volume":"24","author":"Akahori","year":"2019","journal-title":"Oncologist"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"26900","DOI":"10.18632\/oncotarget.24809","article-title":"Liquid biopsy in pancreatic cancer: The beginning of a new era","volume":"9","author":"Yadav","year":"2018","journal-title":"Oncotarget"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.molonc.2015.11.012","article-title":"Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer","volume":"10","author":"Tjensvoll","year":"2016","journal-title":"Mol. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.18632\/oncotarget.23330","article-title":"Targeted deep sequencing of circulating tumor DNA in metastatic pancreatic cancer","volume":"9","author":"Berger","year":"2018","journal-title":"Oncotarget"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/bjc.2017.479","article-title":"KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: A retrospective study","volume":"118","author":"Nakano","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1200\/JCO.2017.35.15_suppl.4101","article-title":"Potential role of circulating tumor DNA (ctDNA) in the early diagnosis and post-operative management of localised pancreatic cancer","volume":"35","author":"Lee","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000354737","article-title":"Analysis of germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations","volume":"85","author":"Fanale","year":"2013","journal-title":"Oncology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","article-title":"CONKO-005: Adjuvant Chemotherapy with Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial","volume":"35","author":"Sinn","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1001\/jama.2013.279201","article-title":"Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: The CONKO-001 randomized trial","volume":"310","author":"Oettle","year":"2013","journal-title":"JAMA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2013.50.7657","article-title":"Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study","volume":"32","author":"Valle","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/0284186X.2015.1068445","article-title":"Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma\u2014A population-based cohort study","volume":"55","author":"Labori","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11605-013-2412-1","article-title":"Treatment sequencing for resectable pancreatic cancer: Influence of early metastases and surgical complications on multimodality therapy completion and survival","volume":"18","author":"Tzeng","year":"2014","journal-title":"J. Gastrointest. Surg."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1245\/s10434-019-07602-6","article-title":"Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival","volume":"26","author":"Altman","year":"2019","journal-title":"Ann. Surg. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: A systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/bjc.2016.222","article-title":"FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret Cancer Centre experience","volume":"115","author":"Chllamma","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_43","unstructured":"Higgins, J.P.T., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons, Ltd."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"Altman","year":"2001","journal-title":"BMJ"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9260","article-title":"Indirect comparisons of competing interventions","volume":"9","author":"Glenny","year":"2005","journal-title":"Health Technol. Assess"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/sim.1201","article-title":"Network meta-analysis for indirect treatment comparisons","volume":"21","author":"Lumley","year":"2002","journal-title":"Stat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res. Synth. Methods"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and Group, P. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_50","unstructured":"(2014). Review Manager (RevMan) [Computer Program], The Nordic Cochrane Centre, The Cochrane Collaboration. version 5.3."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/jhbp.15","article-title":"Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: Project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery","volume":"21","author":"Motoi","year":"2014","journal-title":"J. Hepato Biliary Pancreat. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:01:52Z","timestamp":1760173312000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/3\/534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":52,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["cancers12030534"],"URL":"https:\/\/doi.org\/10.3390\/cancers12030534","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,26]]}}}